BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer.
Bromodomain and extraterminal motif proteins inhibitor (BETi)
Enhancer of zeste homolog 2 inhibitor (EZH2i)
Epigenetic agents
Hematological malignancies
Solid tumors
Journal
Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967
Informations de publication
Date de publication:
04 02 2019
04 02 2019
Historique:
entrez:
5
2
2019
pubmed:
5
2
2019
medline:
23
6
2020
Statut:
epublish
Résumé
Increasing evidence suggests that epigenome plays a central role in cancer development making it a promising target for anticancer treatments. Here, we review two new classes of epigenome-targeting agents: the bromodomain and extraterminal domain proteins (BET) inhibitors and the enhancer of zeste homolog (EZH2) inhibitors. Clinical research evaluating BET and EZH2 inhibitors is still at an early stage; however, both classes of drugs have demonstrated activity among different hematologic malignancies and solid tumors. Several studies on BETi and EZH2i are ongoing to better define their potential role in cancer treatment, which patients are most likely to benefit and if the association with other drugs can improve their efficacy.
Identifiants
pubmed: 30715616
doi: 10.1007/s11912-019-0762-x
pii: 10.1007/s11912-019-0762-x
doi:
Substances chimiques
Antineoplastic Agents
0
Proteins
0
bromodomain and extra-terminal domain protein, human
0
EZH2 protein, human
EC 2.1.1.43
Enhancer of Zeste Homolog 2 Protein
EC 2.1.1.43
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
13Références
Nat Immunol. 2003 Feb;4(2):124-31
pubmed: 12496962
J Clin Oncol. 2002 May 15;20(10):2429-40
pubmed: 12011120
Cell Mol Life Sci. 2006 Dec;63(23):2755-63
pubmed: 17013555
Cancer. 2006 Apr 15;106(8):1794-803
pubmed: 16532500
Blood. 2007 Jan 1;109(1):52-7
pubmed: 16882708
Nat Med. 2012 Feb 06;18(2):298-301
pubmed: 22237151
Nature. 2014 Jun 12;510(7504):278-82
pubmed: 24759320
Lancet Haematol. 2016 Apr;3(4):e196-204
pubmed: 27063978
Transcription. 2013 Jan-Feb;4(1):13-7
pubmed: 23131666
EMBO J. 2003 Oct 15;22(20):5323-35
pubmed: 14532106
J Biol Chem. 2008 Apr 4;283(14):9040-8
pubmed: 18223296
Cancer Cell. 2012 Oct 16;22(4):506-523
pubmed: 23079660
Oncotarget. 2011 Sep;2(9):669-83
pubmed: 21941025
Blood. 2011 Jun 2;117(22):5827-34
pubmed: 21355097
Mol Cell Biol. 2009 Sep;29(18):5094-103
pubmed: 19596781
Drug Discov Today. 2018 Jan;23(1):76-89
pubmed: 28943305
Cancer Discov. 2016 May;6(5):492-500
pubmed: 26976114
Cancer Discov. 2018 Jan;8(1):24-36
pubmed: 29263030
Nature. 2012 Dec 6;492(7427):108-12
pubmed: 23051747
Cancer Res. 2013 Oct 15;73(20):6264-76
pubmed: 23950209
Oncogene. 2011 Sep 29;30(39):4118-28
pubmed: 21499305
Nature. 2011 Jan 20;469(7330):343-9
pubmed: 21248841
Cancer Genet Cytogenet. 2010 Nov;203(1):16-20
pubmed: 20951314
Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8538-43
pubmed: 9671713
Blood. 2013 May 30;121(22):4512-20
pubmed: 23529930
Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S4-11
pubmed: 16341240
Curr Hematol Malig Rep. 2018 Oct;13(5):369-382
pubmed: 30112706
Nat Chem Biol. 2012 Nov;8(11):890-6
pubmed: 23023262
Leuk Lymphoma. 2018 Jul;59(7):1574-1585
pubmed: 29473431
Mol Cancer Ther. 2009 Jun;8(6):1579-88
pubmed: 19509260
Cell. 2013 Apr 11;153(2):320-34
pubmed: 23582323
Lancet Oncol. 2018 May;19(5):649-659
pubmed: 29650362
Leukemia. 2013 Jun;27(6):1301-9
pubmed: 23486531
Nature. 2011 Aug 03;478(7370):524-8
pubmed: 21814200
Biochem Biophys Res Commun. 1983 Feb 28;111(1):47-54
pubmed: 6187346
J Clin Oncol. 2010 Feb 1;28(4):556-61
pubmed: 20026803
Proc Natl Acad Sci U S A. 2013 May 7;110(19):7922-7
pubmed: 23620515
Blood. 2011 Oct 6;118(14):3932-41
pubmed: 21828135
Oncotarget. 2015 Jul 10;6(19):17698-712
pubmed: 25989842
PLoS One. 2013 Apr 17;8(4):e61341
pubmed: 23613835
Cancer. 2012 Feb 15;118(4):1014-22
pubmed: 21761399
Blood. 2007 Jan 1;109(1):31-9
pubmed: 16960145
Proc Natl Acad Sci U S A. 2012 May 1;109(18):6927-32
pubmed: 22509028
Nat Rev Genet. 2006 Jan;7(1):21-33
pubmed: 16369569
PLoS One. 2013 Aug 15;8(8):e71670
pubmed: 23967231
Lancet Oncol. 2014 Oct;15(11):1195-206
pubmed: 25242045
Cell Growth Differ. 2000 Aug;11(8):417-24
pubmed: 10965846
Cancer Cell. 2010 Oct 19;18(4):316-28
pubmed: 20951942
Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21360-5
pubmed: 23236167
Expert Opin Ther Pat. 2017 Jul;27(7):797-813
pubmed: 28394193
J Clin Oncol. 2012 Jul 20;30(21):2670-7
pubmed: 22689805
Biol Pharm Bull. 2012;35(11):2064-8
pubmed: 22971749
J Clin Oncol. 2007 Jul 20;25(21):3109-15
pubmed: 17577020
J Proteome Res. 2006 Mar;5(3):502-11
pubmed: 16512664
Drug Discov Today Technol. 2017 Jun;24:19-24
pubmed: 29233295
Mol Cell. 2008 Apr 11;30(1):51-60
pubmed: 18406326
J Clin Oncol. 2009 Aug 10;27(23):3842-8
pubmed: 19528372
Acta Otorrinolaringol Esp. 2008 Feb;59(2):62-9
pubmed: 18341862
Lancet Haematol. 2016 Apr;3(4):e186-95
pubmed: 27063977
J Clin Oncol. 2009 Nov 10;27(32):5410-7
pubmed: 19826128
Science. 2008 Dec 12;322(5908):1695-9
pubmed: 19008416
Blood. 2010 Dec 9;116(24):5247-55
pubmed: 20736451
Theranostics. 2016 Jan 01;6(2):219-30
pubmed: 26877780
Cell Rep. 2016 Sep 13;16(11):2829-2837
pubmed: 27626654